Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00094367 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
NCT00094367: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00094367 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 900 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00094367, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
Study Summary
This study was designed to evaluate if subjects who took 600 mg of abacavir and 300 mg of lamivudine once-daily as a single tablet were just as likely to have adverse events compared to subjects who took 300 mg of abacavir and 150 mg of lamivudine administered as separate tablets twice-daily.
Interventions
- DRUG Abacavir/Lamivudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2004-07 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
What the finished NCT00094367 record still lists
NCT00094367 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 1 intervention - of which Abacavir/Lamivudine is the first listed.
NCT00094367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00094367 about?
NCT00094367 is a clinical study titled "A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)". This study was designed to evaluate if subjects who took 600 mg of abacavir and 300 mg of lamivudine once-daily as a single tablet were just as likely to have adverse events compared to subjects who took 300 mg of abacavir and 150 mg of lamivudine administered as separate tablets twice-daily.
What is the current status of trial NCT00094367?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2004-07. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00094367?
The interventions under investigation include: Abacavir/Lamivudine (DRUG).
Who is sponsoring clinical trial NCT00094367?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00094367's enrollment target sits among peer trials
900 350th of 2000 higher than 1,641 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia